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Abstract
Background: Cellular senescence is a major barrier to tumour progression, though its role in pathogenesis of
cancer and other diseases is poorly understood in vivo. Improved understanding of the degree to which latent
senescence signalling persists in tumours might identify intervention strategies to provoke “accelerated
senescence” responses as a therapeutic outcome. Senescence involves convergence of multiple pathways and
requires ongoing dynamic signalling throughout its establishment and maintenance. Recent discovery of several
new markers allows for an expression profiling approach to study specific senescence phenotypes in relevant tissue
samples. We adopted a “senescence scoring” methodology based on expression profiles of multiple senescence
markers to examine the degree to which signals of damage-associated or secretory senescence persist in various
human tumours.
Results: We first show that scoring captures differential induction of damage or inflammatory pathways in a series
of public datasets involving radiotherapy of colon adenocarcinoma, chemotherapy of breast cancer cells, replicative
senescence of mesenchymal stem cells, and progression of melanoma. We extended these results to investigate
correlations between senescence score and growth inhibition in response to ~1500 compounds in the NCI60
panel. Scoring of our own mesenchymal tumour dataset highlighted differential expression of secretory signalling
pathways between distinct subgroups of MPNST, liposarcomas and peritoneal mesothelioma. Furthermore, a pro-
inflammatory signature yielded by hierarchical clustering of secretory markers showed prognostic significance in
mesothelioma.
Conclusions: We find that “senescence scoring” accurately reports senescence signalling in a variety of situations
where senescence would be expected to occur and highlights differential expression of damage associated and
secretory senescence pathways in a context-dependent manner.
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B a s e do no b s e r v a t i o n si na g e i n gc u l t u r e dn o r m a lc e l l s ,
cellular senescence has traditionally been regarded as a
permanent cell cycle arrest state which presents a major
barrier to uncontrolled cellular proliferation and tumour
development [1]. The role of telomeres in initiation of
physiological replicative senescence in such cells is now
firmly established, in which failure of the protective cap
Shelterin on highly shortened structurally dysfunctional
telomeres causes direct engagement of the DNA
damage signalling machinery [2]. In addition to divi-
sion-associated telomere attrition, several other stimuli
provoke a rapid senescence response including DNA
damaging insults and supra-physiological expression of
oncogenes [3,4]. To acquire a fully transformed pheno-
type, cancer cells must bypass senescence induced by
such stimuli and continue to proliferate, commonly by
inactivation of core sentinels of cellular stress such as
p53 and pRb [5]. An interesting corollary of findings
that appropriate molecularly targeted interventions are
able to bypass and even reverse established senescence,
suggest that the phenotype is likely to be considerably
more plastic and its control more dynamic than
previously envisaged [6,7].
In the context of cancer therapy, it is now clear that
both radiotherapy and chemotherapeutic agents provoke
a rapid cell cycle arrest response termed “accelerated
senescence”. Seminal observations from an apoptosis
deficient mouse model indicated that senescence contri-
butes to anti-tumour efficacy of cyclophosphamide [8],
and many other cytotoxic agents have been found to eli-
cit accelerated senescence in cancer cells at substantially
lower doses than those required to promote apoptosis.
Therefore, despite inactivation of some key pathways,
many tumour cells retain the ability to exit the cell
cycle under appropriate treatments. Although physio-
logical and accelerated senescence share many morpho-
logical and molecular similarities, some potentially
important differences between the phenotypes have
been observed such as differential regulation of methyla-
tion control pathways [9]. Therefore understanding
both the mechanisms behind senescence in different cell
and tissue types in response to different agents and
the activity of those pathways in vivo is of growing
importance.
For some years, detection of senescence in tissue culture
systems relied primarily on phenotypic changes such as
morphological alterations and b-galactosidase staining [10]
with a few well established molecular markers such as p16
and p21 expression. However, evidence is accumulating to
suggest that senescence should not be regarded exclusively
in terms of the activity a small number of molecules.
Rather, it is perhaps best viewed as a larger signalling
pathway or a new ontology, wherein complex and tightly
regulated gene expression programmes integrate diverse
cell-autonomous and non-autonomous processes. Recent
studies have both improved the mechanistic understand-
ing of senescence and provided new molecular markers
through identification of phenomena such as telomere
induced DNA damage foci, senescence associated hetero-
chromatin foci and the senescence associated secretory
phenotype [11-13]. Availability of these new markers pro-
vides an opportunity for a “pathway-directed” expression
profiling approach in relevant tissues using multi-gene sig-
natures relating to divergent aspects of senescence
signalling.
In this study we used a DNA damage associated
senescence (DAS) signature and a modified secretory
senescence (mSS) signature compiled from recent data
on senescence associated gene expression [11,12,14-23]
to probe publicly available tumour gene expression
data sets and our own mesenchymal tumour set using a
scoring approach based on relative expression of pro-
and anti-senescence markers. We first validated the
approach using public data sets involving interventions
in which increased senescence would be expected. The
sets chosen for this analysis examine radiotherapy of
colon adenocarcinoma [24], doxorubicin and 5-FU treat-
ment of breast cancer cell lines [25], and replicative
senescence of mesenchymal stem cells [26]. In each
case, we find that the scoring approach does indeed
report increased pro-senescence signalling and allows
dissection of the relative contributions of DAS and mSS
subtypes. In another public dataset [27] we found that
senescence signalling increases during melanoma pro-
gression, presumably reflecting multi-step bypass of
tumour suppression programmes.
Having validated the approach in several situations
in which senescence is expected we investigated corre-
lations between senescence score and growth inhibi-
tion in response to ~1500 compounds screened for
toxicity against the NCI60 panel. We examined rela-
tionships between DAS or mSS expression and com-
pound sensitivities and, through chemoinformatic
prediction of compound activities, we investigated the
representation of pharmacophores against several
broad protein target classes in the significant DAS or
mSS related compound set. Finally, we performed an
in-depth examination of the mSS signature in our own
mesenchymal tumour typeset comprising 24 liposarco-
mas, 16 malignant peripheral nerve sheath tumours
(MPNST) and 20 peritoneal mesotheliomas [28].
Through the use of hierarchical clustering we exam-
ined expression patterns and resulting tumour group-
ings in relation to histological characteristics and
outcome.
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Development of senescence scoring approach
Bypass of senescence is a requirement for full transfor-
mation. However, many cancer cells retain the ability to
undergo senescence in response to genotoxic insults
[3,4]. Therefore, tumours must retain extant senescence
pathways, though it is unclear how their expression is
changed during the process of transformation in differ-
ent cells and whether these expression levels might
relate to the propensity to undergo cell cycle arrest in
response to appropriate therapeutic intervention. In this
study we have explored the use of a senescence scoring
approach based on expression profiling of well-defined
senescence markers as a means to evaluate latent senes-
cence pathways in relevant samples. Published literature
was mined for gene expression signatures and biomarkers
of senescence (Table 1) and two sub-signatures were
established. DAS biomarkers represent genes with known
roles in senescence from literature involving DNA
damage and chromatin responses [29-31]. Additionally, a
modified secretory senescence (mSS) signature was cre-
ated by combination of senescence messaging secretome/
senescence associated secretory phenotype (SMS/SASP)
signatures with a signature of 4 genes representing
DNA damage and telomere dysfunction which increase
in expression/activity in senescent cells and are detect-
able in serum of ageing human patients [11,12,14,15].
At present our measure of the senescence response
relies on relative expression of individual biomarkers.
We propose that with an ever increasing number of
genes associated with the senescence response it
should be viewed as a new ontological process consist-
ing of a complex network of gene expression and sig-
nalling pathways. To demonstrate this point Figure 1
shows known functional relations between the genes in
Table 1, which are present in the MetaCore interac-
tions database from GeneGo Inc [32]. Additionally, the
figure shows representative GO processes for each
gene, which further illustrates the cooperation of
diverse processes of damage and inflammation in
senescence.
To assign senescence scores, microarray data was
imported into BRB ArrayTools [33] and filtered to show
only those genes associated with senescence. Data was
normalised to a median value across all arrays to make
all data relative to a median value of 1. Therefore genes
with expression greater than 1 were up-regulated and
less than 1 down-regulated. Each gene was scored as
senescent or not depending on whether expression was
in a pro-senescence direction (see Table 1) with refer-
ence to the median expression level. For example,
expression of the proliferation-associated gene KI67
below median would be marked “senescent” but above
median expression would not. The number of genes
marked “senescent” was then calculated for each sample
and expressed as a percentage of the total number of
genes expressed in each particular signature, all biomar-
kers in Table 1, DAS biomarkers only and mSS biomar-
kers only, to give an overall senescence score for each
signature. By this approach, we hypothesised that the
level of pro-senescence signalling in each pathway can
be measured. Although very simple mathematically, tak-
ing the percentage of genes still signalling in a senescent
manner provides a single continuous senescence mea-
surement in human tumours incorporating the sum
contributions of many pathways, something which has
not previously been reported. In addition the scoring
workflow could be used as a hypothesis driving tool to
investigate the effect of modulating the expression of
different genes in the senescence signalling network or
indeed applied to other biological scenarios by integrat-
ing alternative expression signatures. We have utilised
this scoring system to perform investigations of senes-
cence signalling in various settings (Figure 2).
Table 1 Gene expression changes and senescence
signatures
Originating Senescence
Signatures
Genes Expression Direction in
Senescence
p16 Increase
HMGA1 Increase
HMGA2 Increase
HIRA Increase
ASF1a Increase
DAS Biomarkers H2AFY Increase
[16,17,19-23] H2AFY2 Increase
PML Increase
MMP3 Increase
53BP1 Increase
p21 Increase
Ki67 Decrease
IL6 Increase
IL8 Increase
PAI1 Increase
IGFBP3 Increase
IGFBP5 Increase
IGFBP7 Increase
IL1A Increase
mSS Biomarkers CXCR2 Increase
[11,12,14,15] IGF1 Decrease
IGF2 Decrease
WNT2 Decrease
CAMP Increase
STMN1 Increase
EEF1A1 Increase
IGF2R Increase
TGFB1 Increase
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therapy
Our first main aim was to establish proof of concept as
to whether our scoring approach can provide a reliable
readout in settings in which senescence would be pre-
dicted to occur. We therefore investigated whether
senescence signalling was altered in tumours and nor-
mal tissue of the colon before and after radiotherapy in
the publicly available dataset GSE15781 (Figure 2).
Examination of all biomarkers showed that tumours had
a higher level of senescence signalling compared to their
respective normal tissues (score 69% and 56%, respec-
tively) (Figure 2A). Furthermore, irradiated tumours
have higher median levels of pro-senescence signalling
than their non-irradiated counterparts (score: 74% in
irradiated tumours compared with 69% in non-
Figure 1 Representative Gene Ontology associations and functional interactions between genes in the senescence scoring signature.
The figure illustrates the cooperation between diverse processes including cell proliferation, chromatin remodelling and stress/inflammatory
responses in the senescence phenotype. Blue and grey boxes represent parent and child GO processes, respectively. Red and green arrows
represent negative and positive regulation, respectively. Mechanism: IE, influence on expression; B, binding; C, cleavage.
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is able to capture increased senescence signalling result-
ing from radiotherapy.
As well as measuring overall senescence signalling, we
assigned scores for the sub-signatures DAS and mSS.
Irradiation of tumours causes high levels of DNA
damage with the aim of causing cell necrosis or apopto-
sis [34]. Figure 2B shows that irradiated normal tissue
has increased median DAS signalling compared to non-
irradiated normal, however the overall spread of the
data is lower in the irradiated normal tissue (50%-87%
in non-irradiated compared to 37%-75% in irradiated
normal). Median DAS signalling in adenocarcinoma is
unchanged by irradiation, although the minimum scores
are at a higher level in irradiated tumours than their
non-irradiated counterparts (62% in irradiated compared
to 50% in non-irradiated adenocarcinoma), suggesting a
trend in favour of higher DAS signalling in irradiated
tumours. Interestingly, irradiation did not increase mSS
signalling in tumours (score: 73% pre- and post-irradia-
tion). In contrast, normal tissues showed a median
increase of 6.7% following irradiation (Figure 2C).
Radiotherapy therefore appears to specifically activate
the DNA damage and chromatin aspects of senescence
whilst not altering levels of the secretory senescence sig-
nalling pathway in tumours. This finding may present
novel opportunities for improved senescence induction
through therapeutic activation of secretory pathways in
these tumours.
Senescence scoring in drug treated breast cancer cells
To assess the performance of the scoring approach in
analysis of drug-induced accelerated senescence, we
examined the public data set GSE1647 in which the
authors investigated drug-specific toxicity-related
expression profiles in a panel of breast cancer cell lines
treated with chemotherapy drugs. Senescence was not
directly assessed in this study, though each drug was
administered at its IC50 for each cell line (assessed by a
mitochondrial dye conversion assay). Because the set
contains few replicates for each treatment, for statistical
robustness we have here pooled data for the 3 cancer
cell lines ZR-75-1, ME16C, and MCF7 treated for 24
hours with either doxorubicin or 5-FU, both of which
have previously been observed to induce the accelerated
senescence phenotype in tissue culture [35,36].
Across all cell lines, the median basal senescence score
is comparatively low (20%). As observed with radiother-
apy of colon adenocarcinoma, treatment with either
5-FU or doxorubicin results in induction of the overall
senescence score (Figure 2A, 5-FU score: 35%; doxorubi-
cin score: 33%). DAS markers have basal expression of
14% in untreated cells. As expected, these genes are
strongly induced, resulting in median scores of 45.5%
and 41% for 5-FU and doxorubicin, respectively (Figure
2B). The mSS component is also induced by 24 hour
drug treatments, though more modestly than the DAS
component, rising to 31% and 28% from a basal level of
25%. Thus, both radiotherapy and chemotherapy induce
multiple senescence markers as expected, though mSS
appears to have a greater contribution in the che-
motherapeutic setting.
Senescence signalling dynamics in human mesenchymal
stem cells
Having shown that the scoring approach reports
increased senescence signalling under therapeutically
relevant conditions of genotoxic stress, we next investi-
gated replicative senescence of human mesenchymal
stem cells (hMSCs). We scored the senescence signalling
signatures at passages 2 to 11 in hMSCs from the same
patient (GSE9593). Prior to passage 11, at which time
hMSCs were completely senescent, the authors of this
study observed continuous changes in the cellular
phenotype including gradual increases in cell size, auto-
fluoresence, SA-bGal staining and osteogenic differentia-
tion potential, while adipogenic differentiation potential
slowly decreased [26]. These results are consistent with
the model of partially stochastic dynamics in replicative
senescence onset that has previously been proposed
[37-39].
Our analysis of all markers (Figure 2A) is consistent
with these observations, indicating that senescence gra-
dually increases with passage. A plateau between pas-
sages 6 and 8 is evident when all markers are scored
(score 79%). Strikingly, however, examination of the
DAS and mSS signatures shows that this plateau is in
fact a timed change in signalling type. Secretory senes-
cence signalling remains level at 75% until passage 6 at
which point a slight reduction to 69% is observed. At
this time point there is a corresponding sharp increase
in DAS signalling (75% to 92%). A subsequent spike in
secretory (mSS) expression (score 81%) occurs at pas-
sage 7, followed by a return to base levels (Figure 2C).
Examination of DAS markers at this time point (Figure
2B) shows a transient decrease in their expression (score
75% compared with 92% at passage 6) before returning
to maximal levels. This time course corresponds with a
transient change in the global expression profile of these
cells observed between passages 6-8 in the original
paper [26].
The dynamics of telomere shortening were not
addressed in the original study. However, P7 occurs
immediately before the onset of the main plateau phase
of growth, suggesting that a significant fraction of cells
may have undergone telomere dysfunction. DAS signal-
ling spikes at P6, prior to the peak in mSS signalling at
P7, raising the intriguing possibility that a threshold
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Page 5 of 16Figure 2 Senescence scoring of public data sets. Datasets tested were: irradiated and non-irradiated colorectal tumour and normal tissue
(GSE15781); doxorubicin and 5-FU treated breast cancer cell lines (GSE1647); mesenchymal stem cells cultured to replicative senescence
(GSE9593); a melanoma progression set (GSE4587). All sets were scored using (A) All markers from Table 1, (B) DAS markers, (C) mSS markers.
Median senescence scores are shown with bars representative of the maximum and minimum values. In the case of the hMSC set, the time-
course data are derived from the cells of a single donor without replication and therefore, no bars are shown.
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cellular stress to the surrounding microenvironment
through the mSS pathway [40]. Notably, the spike in
secretory signalling also correlates with a transient
increase in expression of glycoprotein GPNMB/osteoac-
tivin which was validated by QPCR in the original study
[26]. GPNMB is an osteoclastic factor also implicated in
endothelial cell adhesion and regulation of pro-inflam-
matory macrophage signalling, supporting the idea that
signalling to the microenvironment is indeed increased
at this time point [41,42]. To our knowledge this is the
first time such a temporal switch in senescence signal-
ling has been documented, however the differential reg-
ulation of secretory and other senescence pathways
during replicative senescence is also concurrent with
our other recent findings in human T-cells during
senescence bypass [43].
Senescence scoring in a Melanoma progression dataset
The above results suggest that the scoring system effec-
tively captures increased activity of senescence pathways
during both accelerated and physiological senescence.
The expression levels of extant senescence pathways are
likely to be altered by the processes of transformation
and tumour progression and may reflect the route to
immortalisation in individual tumour types. However,
these questions have not yet been substantially investi-
gated. We therefore examined the changes in senescence
signalling during tumour progression in a melanoma
dataset (GSE4587). Figure 2 shows levels of senescence
signalling in benign nevi (score 55%, for all markers).
Interestingly, an increased senescence score was found
in melanoma when compared to benign nevi, regardless
of the type of senescence signalling explored (DAS
score: 58% versus 50%; mSS score 75% versus 63%).
Although transformation has been achieved in these
melanomas some aspects of the senescence program
still appear to be active. The specific identities of
induced senescence genes during tumour progression
may point to the route of immortalisation for specific
tumour types.
Comparison of primary melanoma and metastasis
using all markers shows a slight increase in metastasis
(melanoma score: 70%; metastasis score: 71.4%) (Figure
2A). However exploration of DAS and mSS reveals
striking differences between the two tumour stages. Pri-
mary melanomas have a high contribution from mSS
signalling and low levels of expression of the DAS bio-
markers (75% and 58% respectively), while metastases
have the opposite expression pattern (DAS score 75%;
mSS score 69%) (Figure 2B and 2C). These results may
suggest that the proinflammatory microenvironment
produced by the secretory senescence signalling pathway
is advantageous to a primary tumour in processes such
as angiogensis. The low DAS senescence scores in pri-
mary tumours may reflect low levels of signalling shortly
after immortalization and senescence bypass. After
which, genomic instability may increase during the pro-
cess of tumour progression leading to higher levels of
DAS senescence signalling pathways in metastasis.
Alternatively, DAS related signalling pathways may be
induced during bypass of anoikis. In summary, these
data suggest that DAS signalling increases during
tumour progression. However these increases are clearly
insufficient to induce cell cycle arrest.
Correlation between senescence score and drug toxicity
in the NCI60 panel
The results above provide proof of concept that senes-
cence scores obtained using these signatures conform
with expectations given current understanding of repli-
cative and accelerated senescence. To extend these
results we investigated the possibility that latent senes-
cence pathways may affect cellular responses to drug-
ging. We first applied the scoring approach to gene
expression data for the NCI60 cell line panel. Since
extensive pharmacological characterisation data is avail-
able in addition to the expression profile in the dataset
GSE5846 it is an ideal test set to examine the relation-
ship between senescence signalling and drug response.
Figure 3A-C show scores for all biomarkers (A), DAS
(B) and mSS (C) in this panel with cell lines divided
according to tissue of origin. For quality assurance pur-
poses we also re-scored our own stock of two of the
NCI60 cell lines, DU145 and HT29 and compared these
results with those of the public dataset (figure 3D).
Although we found somewhat lower scores overall, the
trend toward higher expression of DAS than mSS is pre-
served in our hands in both lines (GSE5846 DAS scores:
75%, both cell lines; GSE5846 mSS scores: 56.3%, both
cell lines; our cells DAS scores: 45.5% and 40.9%; our
cells mSS scores: 33.3%, both lines).
Each tissue of origin had an individual scoring range
profile. Comparison of scoring revealed clear divergence
between DAS and mSS in some tissues. However in
general DAS scores were higher than mSS. For example,
leukaemia and colorectal cell lines generally scored
more highly for expression of DAS markers than mSS
(median scores: 66.7% (leukaemia), 75% (colorectal),
DAS; 53.1% (leukaemia) and 50% (colorectal), mSS).
Conversely CNS cell lines showed slightly higher mSS
expression (mSS median score: 71.9%; DAS median score:
70.8%). These differences may reflect common routes to
tumorigenesis and/or microenvironmental interactions in
these tumour types. For example, increased secretion
of pro-inflammatory and chemotactic molecules might
be expected to select against blood-borne tumours
whereas in solid tumours of immune privileged sites
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angiogenesis.
To explore the relationship between senescence sig-
nalling and drug induced toxicities in this panel, we ana-
lysed GI50 data for ~1500 compounds, tested at least
four times against each of the cell lines, as described in
a previous study by Scherf et al [44]. One finding pre-
sented in the original study, is a 1376 gene signature
capable of clustering the cell lines according to their
drug sensitivity patterns assessed by GI50.T od e t e r m i n e
if senescence signalling affects drug sensitivities, we per-
formed regression analyses comparing the GI50 scores of
each drug across the cell panel with senescence scores
for DAS and mSS. Examples of significant regressions
using the DAS and mSS signatures are shown in figures
4A and 4B, respectively, for compounds NSC300288
(p = 0.0015, slope = -3.34) and NSC638279 (p = 0.0002,
slope = -4.04). Examination of regression trends across
the compound set revealed 78 and 328 compounds with
unique significant relationships (regression p < 0.05)
between growth inhibition and DAS or mSS expression
respectively, with a further 5 compounds displaying a
relationship to both signatures (figure 4C). To explore
the contribution of each signature to drug resistance or
sensitivity we examined direction and slope of each
unique significant regression for DAS or mSS (Figure 4D
shows the mean value across all significant compounds
unique for each signature). This analysis revealed that
cell lines with high DAS and high mSS are generally
more sensitive to compound induced growth inhibition,
as shown by the overall negative regression slopes (aver-
age DAS slope = -2.41; average mSS slope = -1.93).
These results suggest that latent expression levels of
these pathways may potentially have a significant
impact on response to some therapies.
Compound activity prediction for significant DAS/mSS
related compounds
To extend our analysis of the relation between DAS/
mSS and drug sensitivity into prediction of target class
Figure 3 Senescence scoring in the NCI60 cell panel. Expression data from set GSE5846 were scored using (A) All markers from Table 1,
(B) DAS markers, (C) mSS markers. Individual scores for each cell line are shown with cell lines separated according to tissue of origin. BR, breast
cancer; CNS, central nervous system; CO, colorectal cancer; LC, lung cancer; LE, leukaemia; ME, melanoma; OV, ovarian cancer; PR, prostate cancer;
RE, renal cancer. (D) Comparison of senescence scoring of public data for HT29 and DU145 cells with our experimental results.
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Page 8 of 16Figure 4 Correlation between senescence scoring and cell line compound sensitivities. Regression analysis was performed comparing DAS
and mSS senescence scores derived from the NCI60 panel (figure 3, dataset GSE5846) with GI50 values for each cell line for ~1500 compounds
reported in [44]. Representative regressions for DAS and compound NSC300288 (A) and mSS and compound NSC638279 (B) are shown.
(C) Quantification of all compounds showing significant regression against DAS or mSS. (D) Characterisation of relationship between DAS/mSS
and drug sensitivity. The slope of the regression for each significant DAS/mSS related compound was quantified. The figure shows the mean
value across all significant compounds. (E) Activity modelling for significant compounds. Compounds were assigned predicted activity based on
a decision tree model relating chemical similarity to a dataset of compounds with known activities. The proportion of compounds from DAS or
mSS significant lists falling into each activity category is shown normalised to target class representation in the total compound set.
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Page 9 of 16sensitivities, we undertook activity modelling for the sig-
nificant compounds using graph-theory connectivity
indices to build a decision tree model based on chemical
similarity with compounds of known activities in the
classes GPCR agonist inhibition, GPCR antagonist inhi-
bition, kinase inhibition, protease inhibition, PDE inhibi-
tion, ligand-gated ion channel inhibition and nuclear
hormone receptor inhibition. We compared the fraction
of assigned predicted activities for each target class in
the DAS/mSS related compounds with those of the
entire test compound set to obtain fold enrichment dis-
tributions as shown in figure 4E.
Protease inhibitor pharmacophores were enriched in
the DAS related compounds compared with their repre-
sentation in the test set (1.05-fold). Interestingly, since
DAS apparently confers sensitivity to these compounds,
these results may suggest that pharmacophores corre-
sponding with existing protease targets may be thera-
peutically favourable in high DAS contexts. In all other
drug categories mSS showed higher enrichment than
DAS, where PDE inhibitor, Ion channel and GPCR
agonist chemotypes were the most enriched in mSS
r e l a t e dc o m p o u n d s( 1 . 3 2 - ,1 . 3 6 -a n d1 . 2 - f o l dr e s p e c -
tively). Since mSS also correlates with increased toxicity,
intervention strategies based on such compounds may
efficiently target mSS expressing tumours.
Differential senescence signalling patterns in
mesenchymal tumours
Finally, to better understand the contribution of senes-
cence signalling to the biology of mesenchymal tumours,
we applied the approach to our own mesenchymally
derived tumour gene expression dataset [28] (previously
published under GSE17118 [45] (Figure 5). Considering
all markers, the median scores were identical across all
tumour types (46% (Figure 5A). Dissection of individual
senescence signalling pathways showed that DAS signal-
ling is lowest in MPNST (42%) and mesotheliomas
(46%) and higher in liposarcoma (score: 50%) (Figure 5B).
In contrast, mSS expression is higher in mesothelioma
(score: 50%) than either MPNST or liposarcomas (44%
and 47%, respectively) (Figure 5C).
These results suggest that even small changes in
senescence signalling pathways can be detected using
this scoring method and allow for hypothesis driven
investigations. For example differences in extant/latent
senescence signalling could affect factors such as patient
prognosis and response to therapy.
We next investigated senescence score in individual
tumour samples. For each senescence signature we
ranked the scores for each tumour within its group to
smooth the data. Ranked data was used to calculate cor-
relation between senescence signatures for each indivi-
dual tumour within the group (Table 2), allowing us to
investigate whether the signatures are distinct signalling
events or can be co-expressed in individual tumours. In
all tumour types investigated both DAS and mSS signa-
tures significantly correlate with All biomarkers (Table
2). Furthermore DAS and mSS never significantly corre-
late, suggesting that these two pathways are distinct sig-
nalling events at an individual tumour level. These data
Figure 5 Senescence scoring of mesenchymal tumours.
Peritoneal mesothelioma, liposarcoma and MPNST samples from set
GSE17118 were scored using (A) All markers from Table 1, (B) DAS
markers, (C) mSS markers. Median senescence scores are shown
with bars representative of the maximum and minimum values.
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nent at the level of individual tumours, implying that
senescence phenotypes may be differentially activated
during transformation.
Supervised Hierarchical clustering using the mSS
signature highlights heterogeneous subgroups within
mesenchymal tumours and a prognostic signature in
peritoneal mesotheliomas
Given the essential nature of the establishment of a
secreted inflammatory network of signalling in senes-
cence induction [46] and our observations of differential
expression patterns of secretory senescence in mesench-
ymal tumours and hMSCs, we used the mSS signature
to further explore senescence signalling patterns in this
pathway in mesenchymal tumours. After normalisation
of gene expression array data, we examined the expres-
sion patterns of only the mSS signature within each
tumour type using supervised hierarchical clustering
(Figure 6A, and data not shown).
Hierarchical clustering in peritoneal mesotheliomas
split these tumours into two distinct groups, A and B
(Figure 6A), corresponding to differential expression in
two gene groups, 1 and 2 (Table 3). Specifically, group
A tumours have higher expression of group 1 genes and
lower expression of group 2 genes than do group B
tumours. The groupings do not significantly correlate
with any patients’ characteristics for which we have
data, such as age or sex (data not shown). Interestingly,
tumours in group A are associated with improved survi-
v a lc o m p a r e dt ot h o s ei ng r o u pBa n dt h i sr e m a i n ss i g -
nificant after adjusting for age and sex (Figure 6B). This
suggests that even though senescence has been
bypassed, the latent expression of different subsections
of the secretory senescence pathway affects patient
outcome.
Analysis of GO processes for these prognostic gene
groups revealed that group 1 genes have functions in
immune activation (p = 4.1E-10), chemotaxis (p = 1.6E-11),
inflammation (p = 1.2E-8) and negative regulation of
cell proliferation (p = 3E-16). This is concurrent with
our previous findings in other tumour types, that
patients with high levels of local inflammation and
immune invasion at the tumour site have improved
survival [47]. Furthermore, the genes in group 2 are
involved with the regulation of cell growth (p = 3.4E-16),
proliferation (p = 2E-13) and cell motion (p = 1.3E-14).
The increased expression of genes involved in cellular
proliferation and cell motion may be indicative of more
aggressive tumours leading to decreased survival rate.
We performed the same analysis on the other two
mesenchymal tumour types. Similar gene groups also split
MPNST into 2 tumour groupings while liposarcomas were
divided into three groups with high group 1 expression
(A), low group 1 expression (B) and low expression of
both groups (C) (data not shown). However, examination
of survival revealed no significant difference between the
groups in these tumours (Figures 6C and 6D). Never-
theless, these expression groups may reflect biological
factors which might warrant further investigation to
improve understanding of the underlying biology and
role of senescence in these subgroups. The same analy-
sis was also carried out using the DAS signature, how-
ever no clear groupings were produced by hierarchical
clustering that would facilitate Kaplan-Meier survival
analysis.
Discussion
To improve the understanding of senescence signalling
it is becoming increasingly necessary to look beyond the
expression of individual genes and at the larger signal-
ling processes they are involved in. Previous studies up
to now have looked at senescence in terms of the
expression of individual biomarkers [11,18,20], however
we propose that senescence signalling may best be
viewed as a network of gene interactions or indeed as a
new gene ontology process as shown in Figure 1. Our
senescence scoring approach allows us to look at senes-
cence in a pathway directed way. By taking a percentage
of the known senescence biomarker genes that are sig-
nalling in a pro- or anti-senescent manner we thereby
reduce the information givenb ym u l t i p l eb i o m a r k e r s
down to one quantifiable number. It is then possible to
dissect the levels of particular senescence signalling
p a t h w a y so c c u r r i n gi nas a m p l ea ta n yo n et i m ea n d
directly compare the levels of these pathways, giving us
an insight into subsystems involved in senescence estab-
lishment and maintenance. In this study we have vali-
dated the approach using a number of publicly available
datasets corresponding to scenarios where modulation
of senescence signalling might be expected. We also
performed an in-depth study into secretory senescence
Table 2 Correlation of senescence score rankings
highlights signalling dynamics in individual tumours
A MPNST All DAS mSS
All 1
DAS 0.738 (p = 0.001) 1
mSS 0.792 (p = <0.001) 0.245 (p = 0.361) 1
B Liposarcoma All DAS mSS
All 1
DAS 0.622 (p = 0.001) 1
mSS 0.756 (p = <0.001) 0.007 (p = 0.974) 1
C Mesothelioma All DAS mSS
All 1
DAS 0.858 (p = <0.001) 1
mSS 0.627 (p = 0.003) 0.164 (p = 0.489) 1
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have shown that senescence signalling occurs in a con-
text dependent manner. In certain situations DAS and
mSS programs coexist, while in others they are distinct
signalling events regulated in a time dependent fashion.
The induction of DNA damage by radiotherapy in
cancer is commonplace in current treatment regimes
[34]. Recent evidence suggests that senescence is fre-
quently induced after radiation exposure [4,48,49].
Through the examination of colon tumours and normal
tissues pre and post radiotherapy from publicly available
data, we aimed to gain a further understanding of the
individual roles of DAS and mSS signalling in this
process. As well as observing a general increase in
senescence signalling post radiation exposure concurrent
with the literature, we have shown that secretory senes-
cence signalling is not induced by radiotherapy in colon
adenocarcinoma, while there is a trend in favour of an
increase in DAS signalling in these samples. To our
knowledge, this distinction has not previously been
made. The scoring method allows us to measure senes-
cence and to form hypotheses on the effect of modulat-
ing the response, for example lower mSS signalling in
adenocarcinoma post-radiotherapy may present impor-
tant opportunities for immune activating adjuvant thera-
pies through the activation of secretory senescence
Figure 6 Supervised hierarchical clustering using the mSS signature highlights gene groups correlating with survival in peritoneal
mesotheliomas. Clustering of mesothelioma samples is shown in (A). Group A tumours had higher expression of group 1 genes and lower
expression of group 2 genes, corresponding to a potential pro-inflammatory phenotype. Gene groups are given in Table 3. (B-D) Kaplan-Meier
survival analyses of tumour groups from mSS supervised hierarchical clustering. (B) Peritoneal mesotheliomas, (C) MPNST and (D) Liposarcoma.
Only mesothelioma samples showed a significant association with survival improvement. P values shown in brackets are p-values after
adjustment for age and sex. All survival analysis performed in SPSS (version 15).
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In addition the observation that cancer cells express
senescence markers, but are able to continue proliferat-
ing suggests that there is a threshold level of expression
for senescence to occur or that key effector molecules are
not present. At present this threshold level is unknown,
however the differential levels of senescence seen in
tumours compared to normal tissues could suggest that
tumours are closer to senescing than their normal coun-
terparts and therefore may signify a therapeutic window,
which could be exploited. These hypotheses can now be
tested experimentally.
We next applied the scoring to a gene expression
dataset comprising doxorubicin or 5-FU treatments of
the breast cancer cell lines ZR-75-1, ME16C, and MCF7
[25]. Here again we found increased representation of
all biomarkers, consistent with the emerging concept of
drug-induced accelerated senescence. The scoring sys-
tem therefore also reported increased senescence in a
second therapeutic intervention scenario. In contrast
with the radiotherapeutic context, both DAS and mSS
subsystems were induced by drug treatments although
induced DAS signalling still predominated. The distinc-
tion between the levels of mSS and DAS in response to
the two treatment types, to our knowledge, has not pre-
viously been documented.
To determine whether the scoring system identified
increased senescence signalling in the normal “physiolo-
gical” context of replicative senescence, we investigated
a time-course dataset corresponding to gradual replica-
tive senescence of hMSCs with increasing passage [26].
Investigation of all biomarkers showed a gradual
increase with passage with a plateau between passages
6-8. By dissection of DAS and mSS elements we found
that this plateau corresponded to a point at which DAS
signalling sharply increased. This was subsequently
followed by an increase in secretory senescence signal-
ling concurrent with a transient decrease in DAS signal-
ling. Such a decrease in DAS signalling may highlight a
specific time-point for the secretory senescence pathway
to signal cellular distress to surrounding cells, as pre-
viously observed in the literature [40] and further high-
lights the distinct nature of the two signalling pathways.
To our knowledge this is the first time such a temporal
switch in senescence signalling has been documented.
Previous data on individual senescence genes in mela-
noma has suggested that senescence is a barrier to
tumour progression [50]. Application of the scoring
approach to a melanoma progression dataset showed
that not only did senescence signalling remain active
after immortalization but that the levels of senescence
signalling of all types in primary tumours were higher
than that seen in benign nevi. This suggests that
although the senescence program has been bypassed the
signalling pathways continue to operate in melanoma.
Furthermore, we found differential expression of secre-
tory and DNA damage/chromatin senescence pathways
in primary lesions and metastasis, with secretory ele-
ments of senescence showing a trend towards down-reg-
ulation in metastases, which may facilitate immune
evasion and disease progression. Despite the down-regu-
lation of secretory senescence the DAS elements of
senescence continue to signal. The latent signalling of
senescence in tumours and metastasis may present
opportunities for therapies to reinstate the correct end-
point of these pathways and halt further disease progres-
sion. Our study therefore suggests that therapies
targeted to induce secretory senescence in metastatic
melanoma may warrant further investigation and
together, the results from these public datasets con-
firmed that the scoring system is able to detect the con-
tribution of individual senescence signalling subsystems
in a variety of contexts.
We therefore investigated a possible relation
between senescence score and compound sensitivities
in the NCI60 panel using growth inhibition data from
~1500 compounds reported in [44]. By regression ana-
l y s i sw ef o u n das u b s e to fc o m p o u n d sf o rw h i c hG I 50
across the cell panel significantly correlated with DAS
or mSS score. Combining all significant results for
either signature, we found an overall negative correla-
tion between DAS and mSS score and GI50, indicating
that high DAS and mSS score may confer sensitivity
to drugging. Modelling of compound activities
revealed overrepresentation of protease inhibitor like
pharmacophores in the DAS subset and ion channel/
PDE inhibitor and GPCR agonist like structures in the
mSS subset. These results indicate that senescence
scores may yield predictive information on cellular
therapeutic sensitivities.
Table 3 Gene groups responsible for clustering in
peritoneal mesotheliomas
Gene Group 1 Gene Group 2
CAMP EEF1A1
EEF1A1 IGF1
IGF2R IGF2
IL1A IGFBP3
IL6 IGFBP5
IL8 IGFBP7
CXCR2 CXCR2
WNT2 PAI1
STMN1
TGFB1
Probes A_32_P47701, A_32_P44316 and A_32_P15320 for EEF1A1 appeared in
group 1 while probe A_24_P763243 featured in group 2. Probe A_23_P135755
for CXCR2 appeared in group 1 while probe A_24_P933228 appeared in
group 2.
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senescence signalling in individual mesenchymally
derived tumours. Initial examination of the correlations
between the rankings of individual tumours from 3
main mesenchymal malignancies, liposarcoma, MPNST
and mesothelioma, highlighted similar patterns of senes-
cence signalling in individual tumours of all 3 tumour
types. Scores for All biomarkers significantly correlated
with those for DAS and mSS in all cases. In contrast
DAS and mSS scores show no correlation suggesting that
these signalling processes are distinct events at an indivi-
dual tumour level. This is consistent with analysis of the
larger tumour groups, where we observed increased mSS
scores in mesothelioma and increased DAS in liposar-
coma in comparison to the other tumour types. As
distinct events we hypothesise that these signalling pro-
cesses may impact upon other clinical factors such as
prognosis or response to treatment.
Previous studies have examined individual senescence
markers and their prognostic significance in these
tumour types [29-31] but not the prognostic significance
of entire senescence signalling pathways. Distinctions
between the different senescence signalling dynamics in
individual tumours gives improved understanding of the
cellular context prior to treatment being applied and
potentially helps to make the move towards patient tai-
lored targeted therapeutics more realistic. Given the
importance of the establishment of a secretory senes-
cence network in the induction of senescence [46] we
hypothesised that t h i sm a yb eap a t h w a yt h a tc o u l db e
perturbed by different mechanisms to effectively prevent
senescence induction. We therefore undertook a more
in-depth analysis of the patterns of expression of secre-
tory senescence in the three mesenchymal tumour types.
Hierarchical clustering of peritoneal mesotheliomas
split the tumours into two groups based on distinct
expression patterns of subsets of secretory senescence
genes involved either in proinflammatory and immune
activating processes or in pro-growth and proliferation
processes. Interestingly, the groupings showed significant
correlation with survival; in particular, those tumours
displaying increased expression of pro-inflammatory
genes had improved survival compared with the lower
expressing group. The functions of these genes are there-
fore likely to be of importance in the underlying tumour
biology of mesotheliomas. Although hierarchical cluster-
ing also divided the MPNST and liposarcoma samples
into 2 and 3 clusters, respectively, based on similar gene
groups, no association with survival was observed.
However, we have previously shown improved survival
associated with tumours with increased immune infiltra-
tion [47] and the activation of specific secretory senes-
cence pathways may facilitate this. Given the secretory
nature of these molecules, their measurement in patient
serum will improve understanding of the role of senes-
cence signalling in patient outcome for these and other
tumour types.
Conclusions
The application of senescence scoring is a useful tool for
assessing senescence signalling in general, as well as
individual senescence pathways, applicable to any gene
expression microarray dataset. The flexibility of this
method facilitates its application to other biological pro-
cesses or modulation of signature content as knowledge
in the field progresses. Application to other tumour
types could also significantly improve our understanding
of senescence signalling in cancer and aid in the devel-
opment of mechanistic studies of these pathways. This
initial study of latent senescence signalling in human
tumours provides a first-glimpse of its potential impor-
tance in tumour biology.
Methods
Senescence scoring of gene expression data
Publicly available or in-house generated gene expression
microarray data files were imported into BRB ArrayTools
(BRB-ArrayTools developed by Dr. Richard Simon and
BRB-ArrayTools Development Team [33]) and filtered
to show only values associated with the senescence sig-
nature gene list in Table 1. Filtered data was then
exported to Microsoft Excel (Microsoft Corp.) for
further analysis. Data was normalised to a median
value calculated across all arrays in that experiment so
that data >1 was up-regulated and <1 down-regulated
relative to a median of 1. Genes were scored as “senes-
cent” or “non-senescent” depending on their gene
expression levels relative to the median and their
known expression pattern during senescence signalling
(see Table 1). For example, expression of the prolifera-
tion-associated gene KI67 below median would be
marked “senescent” but above median expression
would not; likewise expression of the cyclin dependent
kinase inhibitor p21 above median would be marked
“senescent” but below median expression would not. The
number of genes signalling in a “senescent” direction was
then summed and represented as a percentage of the
total number of genes expressed from the senescence sig-
nature. For example, when 20 of the 28 genes in Table 1
were expressed and 16 genes were signalling in a pro-
senescent manner the score was 80%.
To calculate DAS and mSS scores data was sorted in
Microsoft Excel and split into the two signature lists.
Scores were calculated as a percentage of only DAS or
mSS expressed genes respectively.
Median, maximum and minimum values were plotted
using Microsoft Excel or Minitab (v15, Minitab Inc,
Coventry, UK).
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Page 14 of 16Correlations of senescence signature rankings
To assess the correlations of senescence scores given to
each individual mesenchymal tumour by each signature
the scores for each tumour were placed into Minitab
(v15, Minitab Inc, Coventry, UK) and rankings for each
signature score and Pearson correlations calculated.
Regression analysis comparing NCI60 GI50 data with
senescence score was performed using the statistical
package of Perl and exporting results to Excel.
Chemoinformatic prediction of compound activities
The dataset was pre-processed to remove couterions,
assign physiological pH-appropriate atomic charges and
add hydrogen atoms. Fifty 2D molecular descriptors were
computed for each compound including Petitjean graph
theory descriptors, Weiner path and polarity descriptors,
GCUT descriptors, Kier and Hall connectivity indices,
Zagreb index, Balaban indices, Van der Waals surface
area and volume descriptors and topological polar
surface area [51]. The descriptors were also computed
fora training dataset of 3,537 publicly-available known
active compounds collated from the PubChem database
and the ChEMBL database (437 kinase inhibitors, 781
protease inhibitors, 806 GPCR agonists, 737 GPCR
antagonists, 100 PDE inhibitors, 297 nuclear hormone
receptor inhibitors and 379 ligand-gated ion channel
inhibitors). This database of known actives was input
to a binary decision tree algorithm, to derive a 7-cate-
gory decision tree using 38/50 descriptors which cor-
rectly classified 62% of the dataset. The decision tree
was subsequently used to predict activities of the
NCI60 test dataset. All modelling conducted within the
MOE software suite (Chemical Computing Group Inc,
1255 University Street, Montreal, Quebec, Canada).
RNA extraction and Gene expression microarray analysis
of Mesenchymal tumours
A subset of 24 liposarcoma samples and 20 peritoneal
mesotheliomas from a larger study population pre-
viously described [52,53] and 16 MPNST were used for
gene expression analysis. All samples were obtained
under local ethical approval. RNA extraction and micro-
array hybridisation was performed as described in
[28,52,53]. Fully MIAME compliant data files have pre-
viously been published under accession number
GSE17118 [45].
Hierarchical Clustering and Survival Analysis
Hierarchical clustering of each tumour type was per-
formed using Spearman correlation, merging branches
with similarity less than 0.01 in Genespring GX (v7.3).
Kaplan-Meier plots of survival and Log Rank (Cox
Regression) tests adjusting for age and sex were per-
formed on all resulting first level clusters of samples in
all 3 tumour types using SPSS (v15, SPSS Inc, Chicago,
Illinois, USA).
Acknowledgements
This work was supported by Cancer Research UK, European Community
grant Health-F2-2007-200950, Glasgow University and Italian Association for
Cancer Research. Conflict-of-Interest and Financial disclosures: None
Author details
1Centre for Oncology and Applied Pharmacology, University of Glasgow,
Cancer Research UK Beatson Laboratories, Garscube Estate, Switchback Road,
Bearsden, Glasgow G61 1BD, UK.
2Molecular Pharmacology Unit, Department
of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto
Nazionale dei Tumori, Via Venezian, 1, 20133 Milan, Italy.
3Cancer Research
Technology Limited, Wolfson Institute for Biomedical research, Gower Street,
London, WC1E 6BT, UK.
4CompChem Solutions, St John’s Innovation Centre,
Cowley Road, Cambridge, CB4 0WS, UK.
Authors’ contributions
WNK conceived and supervised the study. KLW, NBJ, KAO and WNK
participated in study design, CJC, AB, KLW, NZ, SBurns, SBoyd, JR and LH
performed data analysis and evaluated results. All authors have read and
approved the final manuscript.
Received: 4 March 2010 Accepted: 1 October 2010
Published: 1 October 2010
References
1. Prieur A, Peeper DS: Cellular senescence in vivo: a barrier to
tumorigenesis. Curr Opin Cell Biol 2008, 20:150-155.
2. Palm W, de Lange T: How shelterin protects mammalian telomeres. Annu
Rev Genet 2008, 42:301-334.
3. Braig M, Schmitt CA: Oncogene-induced senescence: putting the brakes
on tumor development. Cancer Res 2006, 66:2881-2884.
4. Gewirtz DA, Holt SE, Elmore LW: Accelerated senescence: an emerging
role in tumor cell response to chemotherapy and radiation. Biochem
Pharmacol 2008, 76:947-957.
5. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P,
Campisi J: Reversal of human cellular senescence: roles of the p53 and
p16 pathways. Embo J 2003, 22:4212-4222.
6. Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY: Escape from therapy-
induced accelerated cellular senescence in p53-null lung cancer cells
and in human lung cancers. Cancer Res 2005, 65:2795-2803.
7. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van
Duijse J, Drost J, Griekspoor A, et al: A genetic screen implicates miRNA-
372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell
2006, 124:1169-1181.
8. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW:
A senescence program controlled by p53 and p16INK4a contributes to
the outcome of cancer therapy. Cell 2002, 109:335-346.
9. Zhang W, Ji W, Yang J, Yang L, Chen W, Zhuang Z: Comparison of global
DNA methylation profiles in replicative versus premature senescence.
Life Sci 2008, 83:475-480.
10. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE,
Linskens M, Rubelj I, Pereira-Smith O, et al: A biomarker that identifies
senescent human cells in culture and in aging skin in vivo. Proc Natl
Acad Sci USA 1995, 92:9363-9367.
11. Kuilman T, Peeper DS: Senescence-messaging secretome: SMS-ing cellular
stress. Nat Rev Cancer 2009, 9:81-94.
12. Young AR, Narita M: SASP reflects senescence. EMBO Rep 2009, 10:228-230.
13. Zhang R, Chen W, Adams PD: Molecular dissection of formation of
senescence-associated heterochromatin foci. Mol Cell Biol 2007,
27:2343-2358.
14. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS,
Desprez PY, Campisi J: Senescence-associated secretory phenotypes
reveal cell-nonautonomous functions of oncogenic RAS and the p53
tumor suppressor. PLoS Biol 2008, 6:2853-2868.
15. Jiang H, Schiffer E, Song Z, Wang J, Zurbig P, Thedieck K, Moes S, Bantel H,
Saal N, Jantos J, et al: Proteins induced by telomere dysfunction and DNA
Lafferty-Whyte et al. BMC Genomics 2010, 11:532
http://www.biomedcentral.com/1471-2164/11/532
Page 15 of 16damage represent biomarkers of human aging and disease. Proc Natl
Acad Sci USA 2008, 105:11299-11304.
16. Reimann M, Lee S, Loddenkemper C, Dorr JR, Tabor V, Aichele P, Stein H,
Dorken B, Jenuwein T, Schmitt CA: Tumor stroma-derived TGF-beta limits
myc-driven lymphomagenesis via Suv39h1-dependent senescence.
Cancer Cell 2010, 17:262-272.
17. Campisi J, d’Adda di Fagagna F: Cellular senescence: when bad things
happen to good cells. Nat Rev Mol Cell Biol 2007, 8:729-740.
18. Collado M, Serrano M: The power and the promise of oncogene-induced
senescence markers. Nat Rev Cancer 2006, 6:472-476.
19. Fridman AL, Tainsky MA: Critical pathways in cellular senescence and
immortalization revealed by gene expression profiling. Oncogene 2008,
27:5975-5987.
20. Narita M: Cellular senescence and chromatin organisation. Br J Cancer
2007, 96:686-691.
21. Sedivy JM, Banumathy G, Adams PD: Aging by epigenetics–a
consequence of chromatin damage? Exp Cell Res 2008, 314:1909-1917.
22. Young AR, Narita M, Ferreira M, Kirschner K, Sadaie M, Darot JF, Tavare S,
Arakawa S, Shimizu S, Watt FM, Narita M: Autophagy mediates the mitotic
senescence transition. Genes Dev 2009, 23:798-803.
23. Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM,
Erzberger JP, Serebriiskii IG, Canutescu AA, Dunbrack RL, et al: Formation of
MacroH2A-containing senescence-associated heterochromatin foci and
senescence driven by ASF1a and HIRA. Dev Cell 2005, 8:19-30.
24. Snipstad K, Fenton CG, Kjaeve J, Cui G, Anderssen E, Paulssen RH: New
specific molecular targets for radio-chemotherapy of rectal cancer. Mol
Oncol 2009, 4:52-64.
25. Troester MA, Hoadley KA, Parker JS, Perou CM: Prediction of toxicant-
specific gene expression signatures after chemotherapeutic treatment of
breast cell lines. Environ Health Perspect 2004, 112:1607-1613.
26. Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V,
Blake J, Pfister S, Eckstein V, Ho AD: Replicative senescence of
mesenchymal stem cells: a continuous and organized process. PLoS One
2008, 3:e2213.
27. Smith AP, Hoek K, Becker D: Whole-genome expression profiling of the
melanoma progression pathway reveals marked molecular differences
between nevi/melanoma in situ and advanced-stage melanomas. Cancer
Biol Ther 2005, 4:1018-1029.
28. Lafferty-Whyte K, Cairney CJ, Will MB, Serakinci N, Daidone MG, Zaffaroni N,
Bilsland A, Keith WN: A gene expression signature classifying telomerase
and ALT immortalization reveals an hTERT regulatory network and
suggests a mesenchymal stem cell origin for ALT. Oncogene 2009,
28:3765-3774.
29. Borczuk AC, Taub RN, Hesdorffer M, Hibshoosh H, Chabot JA, Keohan ML,
Alsberry R, Alexis D, Powell CA: P16 loss and mitotic activity predict poor
survival in patients with peritoneal malignant mesothelioma. Clin Cancer
Res 2005, 11:3303-3308.
30. Oda Y, Yamamoto H, Takahira T, Kobayashi C, Kawaguchi K, Tateishi N,
Nozuka Y, Tamiya S, Tanaka K, Matsuda S, et al: Frequent alteration of p16
(INK4a)/p14(ARF) and p53 pathways in the round cell component of
myxoid/round cell liposarcoma: p53 gene alterations and reduced p14
(ARF) expression both correlate with poor prognosis. J Pathol 2005,
207:410-421.
31. Watanabe T, Oda Y, Tamiya S, Kinukawa N, Masuda K, Tsuneyoshi M:
Malignant peripheral nerve sheath tumours: high Ki67 labelling index is
the significant prognostic indicator. Histopathology 2001, 39:187-197.
32. Bilsland AE, Hoare S, Stevenson K, Plumb J, Gomez-Roman N, Cairney C,
Burns S, Lafferty-Whyte K, Roffey J, Hammonds T, Keith WN: Dynamic
telomerase gene suppression via network effects of GSK3 inhibition.
PLoS One 2009, 4:e6459.
33. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y: Analysis of Gene
Expression Data Using BRB-Array Tools. Cancer Inform 2007, 3:11-17.
34. Ross GM: Induction of cell death by radiotherapy. Endocr Relat Cancer
1999, 6:41-44.
35. Bu X, Le C, Jia F, Guo X, Zhang L, Zhang B, Wu M, Wei L: Synergistic effect
of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and
cell senescence in hepatocarcinoma cells. Cancer Biol Ther 2008,
7:392-396.
36. Sliwinska MA, Mosieniak G, Wolanin K, Babik A, Piwocka K, Magalska A,
Szczepanowska J, Fronk J, Sikora E: Induction of senescence with
doxorubicin leads to increased genomic instability of HCT116 cells. Mech
Ageing Dev 2009, 130:24-32.
37. Britt-Compton B, Rowson J, Locke M, Mackenzie I, Kipling D, Baird DM:
Structural stability and chromosome-specific telomere length is
governed by cis-acting determinants in humans. Hum Mol Genet 2006,
15:725-733.
38. Passos JF, Saretzki G, Ahmed S, Nelson G, Richter T, Peters H, Wappler I,
Birket MJ, Harold G, Schaeuble K, et al: Mitochondrial dysfunction
accounts for the stochastic heterogeneity in telomere-dependent
senescence. PLoS Biol 2007, 5:e110.
39. von Zglinicki T: Oxidative stress shortens telomeres. Trends Biochem Sci
2002, 27:339-344.
40. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR,
Freund A, Campeau E, Davalos AR, Campisi J: Persistent DNA damage
signalling triggers senescence-associated inflammatory cytokine
secretion. Nat Cell Biol 2009, 11:973-979.
41. Pahl MV, Vaziri ND, Yuan J, Adler SG: Upregulation of Monocyte/
Macrophage HGFIN (Gpnmb/Osteoactivin) Expression in End-Stage Renal
Disease. Clin J Am Soc Nephrol 2009, 5:56-61.
42. Sheng MH, Wergedal JE, Mohan S, Lau KH: Osteoactivin is a novel
osteoclastic protein and plays a key role in osteoclast differentiation and
activity. FEBS Lett 2008, 582:1451-1458.
43. Degerman S, Siwicki JK, Osterman P, Lafferty-Whyte K, Keith WN, Roos G:
Telomerase upregulation is a postcrisis event during senescence bypass
and immortalization of two Nijmegen breakage syndrome T cell
cultures. Aging Cell 9:220-235.
44. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW,
Reinhold WC, Myers TG, Andrews DT, et al: A gene expression database
for the molecular pharmacology of cancer. Nat Genet 2000, 24:236-244.
45. Lafferty-Whyte K, Bilsland A, Hoare SF, Burns S, Zaffaroni N, Cairney CJ,
Keith WN: TCEAL7 inhibition of c-Myc activity in alternative lengthening
of telomeres regulates hTERT expression. Neoplasia 2010, 12:405-414.
46. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R,
Desmet CJ, Aarden LA, Mooi WJ, Peeper DS: Oncogene-induced
senescence relayed by an interleukin-dependent inflammatory network.
Cell 2008, 133:1019-1031.
47. Roxburgh CSD, Salmond JM, Horgan PG, Oien KA, McMillan DC: Tumour
inflammatory infiltrate predicts survival following curative resection for
node-negative colorectal cancer. European Journal of Cancer 2009.
48. Jones KR, Elmore LW, Jackson-Cook C, Demasters G, Povirk LF, Holt SE,
Gewirtz DA: p53-Dependent accelerated senescence induced by ionizing
radiation in breast tumour cells. Int J Radiat Biol 2005, 81:445-458.
49. Quick QA, Gewirtz DA: An accelerated senescence response to radiation
in wild-type p53 glioblastoma multiforme cells. J Neurosurg 2006,
105:111-118.
50. Bennett DC: How to make a melanoma: what do we know of the
primary clonal events? Pigment Cell Melanoma Res 2008, 21:27-38.
51. Maldonado AG, Doucet JP, Petitjean M, Fan BT: Molecular similarity and
diversity in chemoinformatics: from theory to applications. Mol Divers
2006, 10:39-79.
52. Cairney CJ, Hoare SF, Daidone MG, Zaffaroni N, Keith WN: High level of
telomerase RNA gene expression is associated with chromatin
modification, the ALT phenotype and poor prognosis in liposarcoma. Br
J Cancer 2008, 98:1467-1474.
53. Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A,
Kusamura S, Baratti D, Deraco M, Costa A, et al: Multiple Mechanisms of
Telomere Maintenance Exist and Differentially Affect Clinical Outcome in
Diffuse Malignant Peritoneal Mesothelioma. Clin Cancer Res 2008,
14:4134-4140.
doi:10.1186/1471-2164-11-532
Cite this article as: Lafferty-Whyte et al.: Scoring of senescence signalling
in multiple human tumour gene expression datasets, identification of a
correlation between senescence score and drug toxicity in the NCI60
panel and a pro-inflammatory signature correlating with survival
advantage in peritoneal mesothelioma. BMC Genomics 2010 11:532.
Lafferty-Whyte et al. BMC Genomics 2010, 11:532
http://www.biomedcentral.com/1471-2164/11/532
Page 16 of 16